DK1290013T3 - Apo-A1/All-peptidderivater - Google Patents

Apo-A1/All-peptidderivater

Info

Publication number
DK1290013T3
DK1290013T3 DK01930664T DK01930664T DK1290013T3 DK 1290013 T3 DK1290013 T3 DK 1290013T3 DK 01930664 T DK01930664 T DK 01930664T DK 01930664 T DK01930664 T DK 01930664T DK 1290013 T3 DK1290013 T3 DK 1290013T3
Authority
DK
Denmark
Prior art keywords
apo
amphipathic helix
domain
helix peptide
peptide
Prior art date
Application number
DK01930664T
Other languages
Danish (da)
English (en)
Inventor
Tadahiko Kohno
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1290013T3 publication Critical patent/DK1290013T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01930664T 2000-04-21 2001-04-23 Apo-A1/All-peptidderivater DK1290013T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19892000P 2000-04-21 2000-04-21

Publications (1)

Publication Number Publication Date
DK1290013T3 true DK1290013T3 (da) 2006-06-26

Family

ID=22735445

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01930664T DK1290013T3 (da) 2000-04-21 2001-04-23 Apo-A1/All-peptidderivater

Country Status (12)

Country Link
US (1) US6743778B2 (https=)
EP (1) EP1290013B1 (https=)
JP (1) JP2003530870A (https=)
AT (1) ATE319737T1 (https=)
AU (2) AU2001257173B2 (https=)
CA (1) CA2407083A1 (https=)
DE (1) DE60117781T2 (https=)
DK (1) DK1290013T3 (https=)
ES (1) ES2260219T3 (https=)
MX (1) MXPA02010324A (https=)
PT (1) PT1290013E (https=)
WO (1) WO2001081376A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US8116889B2 (en) * 2002-06-27 2012-02-14 Openpeak Inc. Method, system, and computer program product for managing controlled residential or non-residential environments
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
WO2006063132A2 (en) * 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007103775A2 (en) * 2006-03-03 2007-09-13 Washington University In St. Louis Biomaterials having nanoscale layers and coatings
CA2653840A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
LT2939683T (lt) 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
KR20240018430A (ko) 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
JP4046354B2 (ja) * 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6156727A (en) 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
GB9815505D0 (en) 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
WO2001081376A3 (en) 2003-01-09
ES2260219T3 (es) 2006-11-01
DE60117781T2 (de) 2006-11-23
EP1290013A2 (en) 2003-03-12
ATE319737T1 (de) 2006-03-15
EP1290013B1 (en) 2006-03-08
PT1290013E (pt) 2006-06-30
DE60117781D1 (de) 2006-05-04
JP2003530870A (ja) 2003-10-21
US6743778B2 (en) 2004-06-01
WO2001081376A2 (en) 2001-11-01
CA2407083A1 (en) 2001-11-01
MXPA02010324A (es) 2003-04-25
AU5717301A (en) 2001-11-07
US20030040470A1 (en) 2003-02-27
AU2001257173B2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
DK1290013T3 (da) Apo-A1/All-peptidderivater
WO2001083527A3 (en) Glucagon antagonists
Atoda et al. The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E
EA200201121A1 (ru) Модуляторы рецепторов паратироидного гормона и родственного паратироидному гормону белка
Hackeng et al. Total chemical synthesis of human matrix Gla protein
US6319897B1 (en) Peptides which inhibit complement activation
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
Choi-Miura et al. Identification of the disulfide bonds in human plasma protein SP-40, 40 (apolipoprotein-J)
McGavin et al. Fibronectin binding determinants of the Staphylococcus aureus fibronectin receptor
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
CA2131389A1 (en) Thrombin receptor antagonists
Himeshima et al. Amino acid sequence of a lectin from the sea cucumber, Stichopus japonicus, and its structural relationship to the C-type animal lectin family
US6469138B1 (en) Thrombospondin receptor binding peptides
WO2001083526A3 (en) Calcitonin-related molecules
Shibata et al. Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide
CA2451741C (en) Peyers's patch and/or m-celle targeting ligands
Bánóczi et al. Synthesis of cell-penetrating conjugates of calpain activator peptides
Thurieau et al. Design and synthesis of new linear and cyclic bradykinin antagonists
DE69732583D1 (de) Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms
WO1996004926A1 (en) TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN
JP2002534996A5 (https=)
Badgery-Parker et al. Receptor binding profile of neuropeptide γ and its fragments: Comparison with the nonmammalian peptides carassin and ranakinin at three mammalian tachykinin receptors
JPH06504260A (ja) 両親媒性ペプチド組成物及びその類似体
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
WO2005041882A3 (en) Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs